| Name | Title | Contact Details |
|---|---|---|
Clay Britton |
Vice President of Legal and Compliance Services and General Counsel | Profile |
Dan Roehler |
Chief Compliance Officer | Profile |
Matt All |
President and Chief Executive officer | Profile |
Scott Raymond |
Vice President of Legal Services and General Counsel | Profile |
BeWellNM has established its online communities to serve as informative and engaging resources for the public. Our goal is to facilitate a constructive, open dialogue around the Patient Protection and Affordable Care Act, and to answer questions relate...
With roots dating back to the 1970s, we are the most experienced provider of hospice care in Michigan. Currently serving more than 1,700 patients daily, in 56 counties, we`re also the largest in our state, and among the largest recognized 501c3 non-profit advanced illness management organizations in the nation. We provide care for all—regardless of age, diagnosis, or ability to pay. Last year, our commitment extended $4 million beyond what was reimbursed by insurance. Because we welcome those who are uninsured, or whose treatment is more expensive than what other hospices can provide, we depend on the financial support of our donors for the treatments, medications, services, grief support, and spiritual care of patients and families in need.
Corona Regional Medical Center is a community hospital network comprised of an acute care hospital and a rehabilitation campus. It is certified by The Joint Commission and has a medical staff of approximately 300 physicians representing more than 40 sp...
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.
ISOAID is a Port Richey, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.